Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals is viewed favorably because its platform is producing multiple late-stage and commercial catalysts across high-value therapeutic areas, including cardiovascular, metabolic, neurological, and rare diseases. The company already has a proven partnering and launch record with Spinraza in 2016, Qalsody in 2023, Wainua in 2024, and first independent launches in 2025 for Tryngolza and Dawnzera, while sefaxersen’s Phase 3 win adds a potential IgAN filing path and tiered royalties in the high teens to 20% on projected €1B-2B peak sales. In addition, Tryngolza’s 85% reduction in acute pancreatitis events over 12 months and the expectation that physician use could rise from a median 6% to 40% by year-end 2027 support a strong commercial outlook, even as execution and payer access remain key variables.

Ionis Pharmaceuticals is viewed negatively because its valuation still depends on a 9% discount rate and 1% terminal growth rate, while key future royalty streams from partnered programs such as sefaxersen and ulefnersen are excluded, leaving the forecast vulnerable if those assets underperform. Commercial execution risk remains elevated, with slower-than-expected TRYNGOLZA uptake, payer restrictions, gross-to-net pressure, and potential launch softness for DAWNZERA, WAINUA PN, or zilganersen all threatening revenue conversion from its broad pipeline. Beyond product-specific uncertainty, regulatory, safety, and manufacturing setbacks, plus higher commercial or R&D spending, could delay the 2028 cash-flow break-even target and pressure investor confidence.